Research Study Summary
ECOG1808-A Randomized Phase II Trial of Sunitinib/Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma with Sarcomatoid Features
Objective- To evaluate response rate of both the combination of sunitinib and gemcitabine and sunitinib alone in patients with advanced renal cell carcinoma with sarcomatoid features. To evaluate progression-free survival following treatment with both the combination of sunitinib and gemcitabine and sunitinib alone in this patient population.
To Learn more
CW ID: 170778
Date Last Changed:
July 22, 2013
Clinical Trial Snapshot
- Both Male and Female
- Overall Status
- Facility Type
DISCLAIMER: CenterWatch does not conduct clinical research.
CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies,
contract research organizations, clinical research sites and other interested parties. This information
is designed to help patients find clinical trials of interest and contact the research centers
conducting the trials.